Selective estrogen receptor modulators in chronic renal failure.
strated that women on dialysis, when compared to nonuremic women, showed elevated baseline estradiol levels which increased significantly after the ingestion of estradiol. This could suggest that renal failure may decrease ESTROGEN AND BONE IN UREMIA estradiol catabolism and affect the pharmacokinetics of The term osteoporosis must be applied with caution exogenous estradiol [13] . Second, a recent study on the in both uremic and patients on dialysis, who have a risks and benefits of estrogen plus progestin in healthy complex range of metabolic bone disease [1]. Neverthepostmenopausal women has introduced a word of cauless, osteoporosis could begin early in time. An importion in HRT therapy [14] . In this randomized controlled tant proportion of young women on dialysis (Ͻ50 years primary prevention trial of the Women's Health Initiaold) are already amenorrheic and relatively hypoestrotive, in which 16,608 postmenopausal women were folgenic with significantly lower bone mineral density lowed for 5.2 years, it was demonstrated that the outcomes were more harmful than beneficial in the estrogen plus progestin group versus the placebo group. Although heart disease increased by 29%, venous thromboembolism was twofold greater, stroke rates were increased by 41%, and invasive breast cancer increased by 26%.
SELECTIVE ESTROGEN RECEPTOR MODULATORS IN HEALTHY WOMEN
Several alternatives are available for women who cannot, or refuse to, take estrogen. Two potential estrogenlike therapies include raloxifene and tamoxifen. These are selective estrogen receptor modulators (SERMs), and they possess tissue-selective estrogen agonist and antagonist properties [15] . In ovariectomized animals, raloxifene preserves bone density, lowers serum total plasia [16] . The mechanism responsible for the apparent tissue-selective activity of raloxifene is not completely understood. In vitro experiments suggest that raloxifene has different effects than estradiol at the estrogen recep-Baseline blood determinations and BMD analysis tor, including differential modulation of DNA response were obtained. Blood was drawn every three months, elements [17] and induction of a different conformational and BMD was evaluated after one year. To investigate change in the transactivation domain of the ligand-bindwhether the ER polymorphism could have predicted the response of BMD to raloxifene in those postmenopausal ing domain [18] . A long-term (40 months) clinical trial, women in chronic hemodialysis, blood was obtained for the Multiple Outcomes of Raloxifene Evaluation (MORE) genomic DNA extraction from peripheral leukocytes. study, involving 7705 postmenopausal women with os-
The ER gene polymorphic region for both PvuII and teoporosis, found that raloxifene's antagonistic effect on XbaI, located in part of intron 1 and exon 2, was amplithe breast appeared to cause a reduction in the risk of fied by PCR using the following primers: breast cancer [19] . Raloxifene did not increase the risk of endometrial cancer, but there was an increased inci-5Ј -CTG CCA CCC TAT CTG TAT CTT TTC CTA dence of thromboembolic disease, hot flashes, influenza-TTC TCC -3Ј like symptoms, peripheral edema, and leg cramps. In 5Ј -TCT TTC TCT GCC ACC CTG GCG TCG ATT this same study, most of the women had lumbar spine ATC TGA -3Ј x-rays at baseline and after 36 months of treatment. Among the women receiving 60 mg raloxifene, 6.6% had After digestion, the products of PvuII and XbaI renew vertebral fractures, compared with 10.1% in the striction fragment length polymorphism (RFLP) were placebo group, but the risk of nonvertebral fractures was submitted to agarose gel electrophoresis. The presence similar. Thus, treatment of uremic women with a SERM, of the restriction site was labeled as p or x alleles (for with their spectrum of breast and uterus antagonist ef-PvuII and XbaI reactions, respectively), and its absence fects, and action on bone as an estrogen agonist, seems as P or X. a less harmful and more rational therapeutic strategy [20] .
Both groups of women were similar regarding age, time on dialysis, time after menopause, medical management of renal osteodystrophy, and degree of osteoporo-SELECTIVE ESTROGEN RECEPTOR sis or osteopenia. Blood biochemical parameters, includ-
MODULATORS IN UREMIC WOMEN
ing serum creatinine, calcium, PTH, and phosphorus, as We have recently analyzed results from a prospective, well as sexual hormone levels (total estradiol, follicle controlled, double-blind study on the effect of raloxifene stimulating hormone, and luteinizing hormone) were on bone and lipid metabolism on postmenopausal also similar in both groups. women on hemodialysis with severe osteopenia (Her-Bone mineral density at the lumbar spine improved ná ndez E et al, in press). Selected women were more significantly after one year of treatment with raloxifene, than 50 years old, had at least two years of menopause, with no change in the placebo group (Fig. 1) . No signifiand evidence of severe osteopenia or osteoporosis (T cant changes were observed at the femoral neck. Likewise, there was a decrease in markers of bone resorption score below Ϫ2.0 SD).
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in high-risk women with respect to coronary and cerebrovascular events. The long-term effect of SERMs in chronic renal failure patients remains to be determined.
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